BLIS TechnologiesNZSE:BLT Current Ratio is 7.56 as of Mar. 2026, which is 21% above its 10-year median of 6.26. The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, BLIS Technologies ranks better than 70.59% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BLIS Technologies's current ratio for the quarter that ended in Mar. 2026 was 7.56.
BLIS Technologies has a current ratio of 7.56. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BLIS Technologies's Current Ratio or its related term are showing as below:
NZSE:BLT'
s Current Ratio Range Over the Past 10 Years
Min: 2.4 Med: 6.26 Max: 8.88
Current: 7.56
During the past 13 years, BLIS Technologies's highest Current Ratio was 8.88. The lowest was 2.40. And the median was 6.26.
NZSE:BLT's Current Ratio is ranked better than 70.59% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs NZSE:BLT: 7.56
BLIS Technologies (NZSE:BLT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BLIS Technologies Current Ratio Related Terms
BLIS Technologies Current Ratio Historical Data
* Premium members only.
The historical data trend for BLIS Technologies's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:BLT vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, BLIS Technologies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLIS Technologies Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLIS Technologies's Current Ratio distribution charts can be found below:
* The bar in red indicates where BLIS Technologies's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLIS Technologies (NZSE:BLT) has a Current Ratio of 7.56 as of Mar. 2026. This is 21% above median its historical median of 6.26. Over the past decade, BLIS Technologies' Current Ratio has ranged from 2.40 to 8.88. According to the industry distribution chart, BLIS Technologies ranks #415 out of 1411 companies in the Biotechnology industry, placing it in the top 29.4%.
Is BLIS Technologies' Current Ratio too high?
BLIS Technologies' current Current Ratio of 7.56 is 21% above median its 10-year median of 6.26. Over the past 10 years, this metric has ranged from a low of 2.40 to a high of 8.88. The Biotechnology industry median Current Ratio is 3.91. BLIS Technologies' value of 7.56 is 93.4% above this industry median. Based on the distribution chart, BLIS Technologies ranks #415 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint.
How does BLIS Technologies' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLIS Technologies ranks #415 out of 1411 companies for Current Ratio. This puts BLIS Technologies in the upper half of its industry. The industry median Current Ratio is 3.91. BLIS Technologies' value of 7.56 is 93.4% above this benchmark. Historically, BLIS Technologies' own Current Ratio has ranged from 2.40 to 8.88 over the past decade. While the company's 10-year median is 6.26 vs. the industry median of 3.91, BLIS Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLIS Technologies's current Current Ratio of 7.56 is 93.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLIS Technologies's current Current Ratio is 7.56, which is 21% above median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLIS Technologies stock overvalued right now?
Based on GuruFocus' analysis, BLIS Technologies (NZSE:BLT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$0.02, compared to a current price of NZ$0.02 — trading 20% below its estimated fair value. The current Current Ratio is 7.56, which is 21% above median its 10-year median of 6.26 and 93.4% above the Biotechnology industry median of 3.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BLIS Technologies (NZSE:BLT), the current Current Ratio is 7.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18, which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from North America. The company also generates a small portion of revenue from Non-core business, which includes grants and interest revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:BLT has been successfully added to your 